
Sign up to save your podcasts
Or
Last December, The BMJ published an investigation into the 2009 PLATO trial - exposing serious problems with that study’s data analysis and reporting. Our follow up investigation has shown that those data problems extend to other key supporting evidence in AstraZeneca’s initial application to regulators.
Peter Doshi, senior editor in the BMJ’s Investigations unit, and Rita Redberg, cardiologist and Professor of Medicine at UCSF and former editor of JAMA Internal Medicine, join us to explain what this means for scientific integrity, and trust in the FDA's approval processes.
Also in this episode. A group of international authors are arguing that weightloss advice given in primary care might actually be doing more harm than good - it’s ineffective and potentially reinforces damaging stigma.
To explain why they came to that conclusion we're joined by Juan Franco editor in chief of BMJ EBM, and a practicing GP in Germany, and Emma Grundtvig Gram, from the Centre for General Practice at the University of Copenhagen
Doubts over landmark heart drug trial: ticagrelor PLATO study
Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug
Beyond body mass index: rethinking doctors’ advice for weight loss
4.4
3030 ratings
Last December, The BMJ published an investigation into the 2009 PLATO trial - exposing serious problems with that study’s data analysis and reporting. Our follow up investigation has shown that those data problems extend to other key supporting evidence in AstraZeneca’s initial application to regulators.
Peter Doshi, senior editor in the BMJ’s Investigations unit, and Rita Redberg, cardiologist and Professor of Medicine at UCSF and former editor of JAMA Internal Medicine, join us to explain what this means for scientific integrity, and trust in the FDA's approval processes.
Also in this episode. A group of international authors are arguing that weightloss advice given in primary care might actually be doing more harm than good - it’s ineffective and potentially reinforces damaging stigma.
To explain why they came to that conclusion we're joined by Juan Franco editor in chief of BMJ EBM, and a practicing GP in Germany, and Emma Grundtvig Gram, from the Centre for General Practice at the University of Copenhagen
Doubts over landmark heart drug trial: ticagrelor PLATO study
Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug
Beyond body mass index: rethinking doctors’ advice for weight loss
129 Listeners
85 Listeners
85 Listeners
4 Listeners
52 Listeners
7 Listeners
5 Listeners
3 Listeners
3 Listeners
4 Listeners
324 Listeners
11 Listeners
38 Listeners
14 Listeners
1 Listeners
44 Listeners
0 Listeners
6 Listeners
14 Listeners
493 Listeners
20 Listeners
3 Listeners
87 Listeners
24 Listeners
134 Listeners
23 Listeners
47 Listeners
11 Listeners
17 Listeners
6 Listeners
4 Listeners
5 Listeners
0 Listeners